Was 4-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?

被引：14
|
作者：
Neuhoff, Sibylle [1 ]
Tucker, Geoffrey T. [2 ]
机构：
[1] Simcyp Certara Ltd, Sheffield, S Yorkshire, England
[2] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2018年 / 84卷 / 07期
关键词：
4-hydroxycholesterol; biomarker; CYP3A4; CONCISE GUIDE; 4-BETA-HYDROXYCHOLESTEROL; METABOLISM; RIFAMPICIN;
D O I：
10.1111/bcp.13538
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1620 / 1621
页数：2
相关论文
共 50 条
  • [41] Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone
    Lee, Lucy
    Thoolen, Martin
    Ma, Jiyuan
    Kaushik, Diksha
    Golden, Lee
    Kong, Ronald
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (12): : 1283 - 1290
  • [42] Electrochemical Assessment of CYP3A4 Catalytic Activity in Bactosomes
    Koroleva, Polina I.
    Kuzikov, Alexey V.
    Gilep, Andrei A.
    Bulko, Tatiana V.
    Shumyantseva, Victoria V.
    BIONANOSCIENCE, 2024, 14 (03) : 2930 - 2939
  • [43] Lacosamide Has No Effect on the Enzymatic Activity of CYP3A4
    Cawello, Willi
    Surmann, Erwin
    Waitzinger, Josef
    NEUROLOGY, 2012, 78
  • [44] Bufalin inhibits CYP3A4 activity in vitro and in vivo
    Li, Hai-yun
    Xu, Wen
    Zhang, Xi
    Zhang, Wei-dong
    Hu, Li-wei
    ACTA PHARMACOLOGICA SINICA, 2009, 30 (05) : 646 - 652
  • [45] Effect of hemodialysis on hepatic CYP3A4 activity.
    Nolin, TD
    Appiah, K
    Kendrick, SA
    Le, P
    McMonagle, E
    Himmelfarb, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P23 - P23
  • [46] PREDICTION OF PARTIAL METABOLIC CLEARANCE OF MIDAZOLAM FROM PARTIAL AUC AS A MARKER OF CYP3A4 ACTIVITY
    Katzenmaier, S.
    Markert, C.
    Mikus, G.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 : 20 - 20
  • [47] Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites
    Sutton, D
    Butler, AM
    Nadin, L
    Murray, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 282 (01): : 294 - 300
  • [48] CYP3A4*16 and CYP3A4*18 Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate Drugs
    Maekawa, Keiko
    Harakawa, Noriko
    Yoshimura, Takuya
    Kim, Su-Ryang
    Fujimura, Yoshiyuki
    Aohara, Fumika
    Sai, Kimie
    Katori, Noriko
    Tohkin, Masahiro
    Naito, Mikihiko
    Hasegawa, Ryuichi
    Okuda, Haruhiro
    Sawada, Jun-Ichi
    Niwa, Takuro
    Saito, Yoshiro
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (12) : 2100 - 2104
  • [49] 4-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?
    Gjestad, Caroline
    Huynh, Duy Khanh
    Haslemo, Tore
    Molden, Espen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (02) : 269 - 276
  • [50] 4β-Hydroxycholesterol as an Endogenous Biomarker of CYP3A Activity in Cynomolgus Monkeys
    Li, Ke
    Zhao, Sylvia
    Zhang, Lingling
    Wu, Xiaoyun
    Shu, Pan
    Wang, Yang
    Feng, Hao
    Gu, Zheming
    Hsu, Helen Han
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (05) : 839 - 843
12345